Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2026 | $67.00 | Neutral → Buy | Goldman |
| 7/10/2025 | $36.00 | Neutral | Goldman |
| 3/25/2025 | $60.00 | Buy | Stifel |
| 2/11/2025 | Buy | TD Cowen | |
| 2/4/2025 | Peer Perform | Wolfe Research | |
| 1/22/2025 | $55.00 | Hold → Buy | Jefferies |
| 3/6/2024 | $68.00 | Buy | Citigroup |
| 1/16/2024 | $50.00 | Overweight | Morgan Stanley |
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00
Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00
Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,
SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents. "BALANCE-CAH is designed to evaluate atumelnant for the treatment of CAH in pediatric age patients – for whom the lifelong burden of this disease begins early," said Dr. Alan Krasner, M.D., Chief Endocrinologist, Crinetics. "For children living with CAH, correcting elevated
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit ("RSU") awards to 10 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)